Navigation Links
Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
Date:6/30/2010

fer and provide contact with its network of physicians and patient organizations. The purchase price is undisclosed but divided into an up-front payment and commercial milestone payments.

The PPS product opportunity is an important means to provide a treatment to a patient group largely suffering without effective medication and to expand sales of immunoglobulin in new patient segments.

About PPS

Several decades after suffering acute polio infection survivors commonly develop PPS characterized by new or increased muscle weakness, fatigue, and pain. Ongoing denervation is the most often suggested for increased muscle weakness associated with polio infection.

Patients with PPS have increased expression of mRNA for proinflammatory cytokines in cerebrospinal fluid which suggests an inflammatory process in the central nervous system. Some patients with asymmetrical weakness have increased wear and tear on joints and muscles, including breathing muscles.

While rarely fatal, the neurological and muscular symptoms of PPS are lifelong and debilitating.

The most recent polio epidemic culminated in the Western countries around 1950. As most infections occur in children, there is nowadays a large pool of polio survivors with varying degrees of functional decline. US National Institute of Neurological Disorders and Stroke (NINDS) gives a prevalence interval for PPS of 25 to 50% (in primary polio infection survivors), WHO estimates a 40 % prevalence; assuming a prevalence of 30%, only in major Western countries there would be around 300,000 PPS patients.

Currently there is no pharmacological treatment for PPS. Several therapeutic agents have failed in achieving positive outcomes. Treatment practices are based on physiotherapy
'/>"/>

SOURCE Pharmalink AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... MILAN , October 27, 2014 ... the right to produce, exhibit and sell its ... sought to impeach their patent.      ... After four years of fighting, the definitive judgement ... designs and produces innovative and accessible hi-tech prostheses ...
(Date:10/27/2014)... October 27, 2014 The “Molecular ... Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End ... Service, Software) - Global Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:10/27/2014)... The report “Smart Highway Market ... Communication, Monitoring), and by Display (Variable Message Signs, ... the global market into various sub-segments with in-depth ... the drivers and restraints for this market with ... 75 market tables and 37 figures spread through ...
(Date:10/27/2014)... 2014 Investor-Edge has initiated coverage ... NBIX ), Insmed Inc. (NASDAQ: INSM ... Dyax Corporation (NASDAQ: DYAX ), and Oncothyreon ... can be accessed at: http://investor-edge.com/register . ... at 4,483.72, up 0.69%, the Dow Jones Industrial Average ...
Breaking Biology Technology:Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... 17 Alfacell Corporation,(Nasdaq: ACEL ) announced ... the,engagement of Oppenheimer & Co. as a financial ... strategic alternatives to enhance,shareholder value, including a possible ... but not be limited to, strategic partnership,transactions., ...
... (MBI) has been awarded a $625,000 contract under ... development of a Universal Sample,Preparation Module (USPM). The ... SBIR firms that have Phase II projects that ... products., MBI,s project will develop a Universal ...
... September 17 Sangui BioTech,International, Inc., is currently preparing ... 30, 2008). The ensuing report on form,10KSB will be ... course. It will be,included in the proxy materials for ... a letter by the SEC. Subsequently, the,shareholders, meeting will ...
Cached Biology Technology:Alfacell Hires Advisors to Advance Strategic Alternatives 2Alfacell Hires Advisors to Advance Strategic Alternatives 3Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program 2Sangui Bio Tech International Inc. Shareholders' Meeting Delayed to Include FY 2008 Report 2
(Date:10/28/2014)... German . ... sufficient food when times are lean? By studying wild ... researchers of the Max Planck Institute for Evolutionary Anthropology ... great apes can acquire extra energy needed to maintain ... sleeping nests more en route to breakfast sites containing ...
(Date:10/28/2014)... Singapore (NTU Singapore) will be building a hybrid ... sources. , The first in the region, the ... of solar, wind, tidal-current, diesel, storage and power-to-gas ... together. , To be built under the new ... hybrid micro-grid will be located offshore at Semakau ...
(Date:10/27/2014)... Ga. – Multiple times each day, about a third ... pressure – for at least an hour after the ... , Now they want to know how chronic mental ... response so they can determine the best ways to ... sodium is bad for you – these patients have ...
Breaking Biology News(10 mins):The early chimp gets the fig 2The early chimp gets the fig 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3Researchers look for the best way to help shake too much sodium 2Researchers look for the best way to help shake too much sodium 3Researchers look for the best way to help shake too much sodium 4
... and the debriefing today, the Russian State Commission has given ... CEST. Today,s go-ahead marks the last milestone along the ... tiny variations in the thickness of ice floating in the ... land, the mission will provide scientists with hard evidence on ...
... of Pittsburgh provides the first identification of a human ... in products from electronics to plasticsand in laboratory tests ... to the tiny components, according to findings published online ... open the door to the use of carbon nanotubes ...
... After years of preparation and anticipation, scientists who discover ... key question about Alzheimer,s disease: Will drugs that block ... called amyloid-beta slow the progression of the devastating disease? ... Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ...
Cached Biology News:CryoSat-2 ready for launch 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 3
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (C6671) or contact customer ... yes Surface area 148 cm 2 ...
Biology Products: